New insider Sauer Noel claimed ownership of 93,730 shares (SEC Form 3)

$CBUS
Agricultural Chemicals
Industrials
Get the next $CBUS alert in real time by email
SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Sauer Noel

(Last) (First) (Middle)
6455 NANCY RIDGE DRIVE

(Street)
SAN DEIGO CA 92121

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
03/24/2025
3. Issuer Name and Ticker or Trading Symbol
Cibus, Inc. [ CBUS ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, Research
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Class A Common Stock 93,730 D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right-to-Buy) (1) 11/11/2034 Class A Common Stock 41,000 $5.75 D
Explanation of Responses:
1. Options vest as to 25% on November 11 of each year between 2025 and 2028
Jason Stokes, Attorney-in-Fact for Noel Sauer 03/28/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $CBUS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CBUS

DatePrice TargetRatingAnalyst
7/29/2024$25.00Buy
Alliance Global Partners
7/19/2024$22.00Buy
Canaccord Genuity
10/9/2023$25.00Buy
H.C. Wainwright
7/19/2023$30.00Buy
Canaccord Genuity
More analyst ratings

$CBUS
Press Releases

Fastest customizable press release news feed in the world

See more
  • Cibus Reports Fourth Quarter Financial Results and Provides Business Update

    A major milestone on March 14th 2025 advanced the EU Trilogue discussions aimed to complete the final text of the New Genomic Techniques (NGTs) or gene editing legislation for the EU; California Rice Commission approved Cibus' field research proposal marking the first time gene edited Rice has been authorized for planting within the state Advancing Rice herbicide tolerance trait commercialization efforts: affirmed strategic collaboration with Albaugh LLC and RTDC Corporation Limited continues to strengthen weed management solutions pipeline as Cibus continues development with four major seed company customers Sclerotinia (White Mold) resistance trait development continues progress with fou

    $CBUS
    Agricultural Chemicals
    Industrials
  • Cibus Welcomes the European Union's Progress as Legislation for New Genomic Techniques to Boost Innovation and Sustainability Moves Forward

    Legislation aims to adapt EU law to reflect scientific and technological progress, enabling the products of New Genomic Techniques (NGTs), such as gene editing, to contribute to more sustainable agriculture, climate resilience, and food security Proposed legislation identifies a ‘conventional-like' category of NGT-1 products that would be regulated as conventional varieties, bringing EU regulation closer to that of other global trading partners The agreement on the Council's negotiating mandate allows its presidency to start negotiations with the European Parliament on the final text of the regulation SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS) (the "Company

    $CBUS
    Agricultural Chemicals
    Industrials
  • Cibus to Report Fourth Quarter 2024 Financial Results on March 20, 2025 After the Market Close and Host Conference Call

    SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report fourth quarter 2024 financial results on Thursday, March 20, 2025. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates. Title: Cibus, Inc. Fourth Quarter 2024 Results Conference Call Event Date: Thursday, March 20, 2025         Time: 4:30 p.m. ET         Participant Numbers: +1-877-300-8521 (U.S.), +1-412-317

    $CBUS
    Agricultural Chemicals
    Industrials

$CBUS
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CBUS
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CBUS
SEC Filings

See more

$CBUS
Leadership Updates

Live Leadership Updates

See more
  • Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer

    EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor. "The addition of Simon, with over 15 years' experience in private capital markets strategy and IPO processes, comes at the right time for Totus as we advance our clinical-stage and discovery programs," said

    $CBUS
    $CLLS
    $MGX
    $CLXT
    Agricultural Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Jim Collins to Join Cibus Board of Directors

    Cibus Announces Election of New Board Member, Deepening Strategic Leadership and Experience SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a global leader in Gene Editing in agriculture and the development of Productivity Traits in plants that directly impact farming productivity and profitability announced that its Board of Directors has elected Jim Collins, former CEO of Corteva, to the Board. "Jim brings to Cibus immense knowledge and strategic vision on the direction of the future role and use of Gene Editing in agriculture," said Mark Finn, Chair of the Audit Committee. "Jim's experience leading one of the largest agricultural and seed companies will gi

    $ADM
    $CBUS
    Packaged Foods
    Consumer Staples
    Agricultural Chemicals
    Industrials
  • Steve Berreth Appointed as General Counsel and Corporate Secretary

    SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, announced today the appointment of Steve Berreth as General Counsel and Corporate Secretary for the corporation. Mr. Berreth was previously Vice President, General Counsel and Secretary for Syngenta Crop Protection LLC, the North American Subsidiary of Syngenta AG, one of the world's largest biotechnology agribusinesses and one of the largest crop protection chemical and seed businesses in the world. He was a member of the Syngenta global legal and compliance leadership teams and led the North American le

    $CBUS
    Agricultural Chemicals
    Industrials

$CBUS
Financials

Live finance-specific insights

See more
  • Cibus to Report Fourth Quarter 2024 Financial Results on March 20, 2025 After the Market Close and Host Conference Call

    SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report fourth quarter 2024 financial results on Thursday, March 20, 2025. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates. Title: Cibus, Inc. Fourth Quarter 2024 Results Conference Call Event Date: Thursday, March 20, 2025         Time: 4:30 p.m. ET         Participant Numbers: +1-877-300-8521 (U.S.), +1-412-317

    $CBUS
    Agricultural Chemicals
    Industrials
  • Cibus Reports Third Quarter Financial Results and Provides Year-to-Date Business Update for 2024

    Announced a strategic realignment to advance commercial opportunities, focusing resources on advancement of weed management platform (HT1 and HT3) for Rice, Pod Shatter Reduction in Canola, Sclerotinia resistance for Canola and Soybean, and on Soybean platform development Great progress in Rice as we execute on our agreements with four major seed company customers in the United States and Latin America, with germplasm received from all customers; completed successful field trials with HT3 in customer germplasm, as well as completed what the Company believes to be the first field trials for stacked gene-edited herbicide tolerance traits Also in Rice, signed an Agreement with RTDC Corporatio

    $CBUS
    Agricultural Chemicals
    Industrials
  • Cibus to Report Third Quarter 2024 Financial Results on November 7, 2024 After the Market Close and Host Conference Call

    SAN DIEGO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that the company will report third quarter 2024 financial results on Thursday, November 7, 2024. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates. Title: Cibus, Inc. Third Quarter 2024 Results Conference Call Event Date: Thursday, November 7, 2024         Time: 4:30 p.m. ET         Participant Numbers: +1-877-300-8521 (U.S.), +1-412-317-6026 (International)         Event Link: https:/

    $CBUS
    Agricultural Chemicals
    Industrials